Replies to post #34636 on Biotech Values

[gofishmarko]

>>> This abstract would seem to imply that the dose of NM283 ought to be raised when given with ribavirin, but this is not what IDIX and NVS are actually doing. Comments? <<<

I'd like to see the full paper to see what they really did. All the abstract says is that riba interferes with NM283 anti-HCV activity. Is riba competing with NM283 in binding to polymerase ? If so , could NM283 interfere with riba's anti-HCV activity(s) ?

It could be that REDUCED doses of both would be optimum. It all depends on the mechanisms and kinetics of activity vs. inhibition of activity. I think IDIX would be awful lucky to get anything like an optimum protocol out of the first study.